Anti-Ischemic Activity of Fabomotizole Hydrochloride under Conditions of Endothelial Dysfunction

  • Bull Exp Biol Med. 2019 Sep;167(5):634-636. doi: 10.1007/s10517-019-04586-x.
I B Tsorin  1 ,  V V Barchukov  1 ,  M B Vititnova  1 ,  S A Kryzhanovskii  2 ,  S B Seredenin  1
Affiliations
  • 1. V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
  • 2. V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia. [email protected].
PMID: 31705224 DOI: 10.1007/s10517-019-04586-x
Abstract

Anti-ischemic activity of fabomotizole hydrochloride was studied on the model of subendocardial ischemia in rats with endothelial dysfunction. Endothelial dysfunction was modeled by intragastric administration of methionine (3 g/kg, once a day for 7 days). Acute subendocardial ischemia was induced in narcotized rats by intraperitoneal injection of isoproterenol (20 μg/kg/min over 5 min). Fabomotizole hydrochloride (intraperitoneally, 15 mg/kg) significantly reduced isoproterenol-induced ST segment depression in Animals with endothelial dysfunction and with intact vasculature.

Keywords
endothelial dysfunction; fabomotizole hydrochloride; subendocardial ischemia; σ1-receptors.
Products